319 related articles for article (PubMed ID: 30514798)
1. Pathogenic immune response to therapeutic factor VIII: exacerbated response or failed induction of tolerance?
Varthaman A; Lacroix-Desmazes S
Haematologica; 2019 Feb; 104(2):236-244. PubMed ID: 30514798
[TBL] [Abstract][Full Text] [Related]
2. Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies.
Scott DW; Pratt KP
Front Immunol; 2019; 10():3078. PubMed ID: 32010137
[TBL] [Abstract][Full Text] [Related]
3. Review of immune tolerance induction in hemophilia A.
Schep SJ; Schutgens REG; Fischer K; Boes ML
Blood Rev; 2018 Jul; 32(4):326-338. PubMed ID: 29482894
[TBL] [Abstract][Full Text] [Related]
4. Factor VIII inhibitors: risk factors and methods for prevention and immune modulation.
Zhang AH; Skupsky J; Scott DW
Clin Rev Allergy Immunol; 2009 Oct; 37(2):114-24. PubMed ID: 19199081
[TBL] [Abstract][Full Text] [Related]
5. Adult haemophilia A patients with inhibitors: successful immune tolerance induction with a single FVIII/VWF product.
Rangarajan S; Jiménez-Yuste V; Santagostino E
Haemophilia; 2014 Nov; 20(6):e414-7. PubMed ID: 25333452
[No Abstract] [Full Text] [Related]
6. Immunological aspects of inhibitor development.
Reding MT
Haemophilia; 2006 Dec; 12 Suppl 6():30-5; discussion 35-6. PubMed ID: 17123391
[TBL] [Abstract][Full Text] [Related]
7. Editorial: Tolerating Factor VIII: Novel Strategies to Prevent and Reverse Neutralizing Anti-FVIII Antibodies.
Lacroix-Desmazes S; Pratt KP
Front Immunol; 2020; 11():639386. PubMed ID: 33569066
[No Abstract] [Full Text] [Related]
8. How we treat a hemophilia A patient with a factor VIII inhibitor.
Kempton CL; White GC
Blood; 2009 Jan; 113(1):11-7. PubMed ID: 18820129
[TBL] [Abstract][Full Text] [Related]
9. Tolerating Factor VIII: Recent Progress.
Lacroix-Desmazes S; Voorberg J; Lillicrap D; Scott DW; Pratt KP
Front Immunol; 2019; 10():2991. PubMed ID: 31998296
[TBL] [Abstract][Full Text] [Related]
10. Domain specificity of factor VIII inhibitors during immune tolerance induction in patients with haemophilia A.
van Helden PM; Kaijen PH; Mauser-Bunschoten EP; Fischer K; van den Berg HM; Voorberg J
Haemophilia; 2010 Nov; 16(6):892-901. PubMed ID: 20491952
[TBL] [Abstract][Full Text] [Related]
11. The importance of inhibitor eradication in clinically complicated hemophilia A patients.
Oldenburg J; Young G; Santagostino E; Escuriola Ettingshausen C
Expert Rev Hematol; 2018 Nov; 11(11):857-862. PubMed ID: 30286680
[TBL] [Abstract][Full Text] [Related]
12. The treatment of factor VIII inhibitors--a general overview.
White GC; Roberts HR
Vox Sang; 1996; 70 Suppl 1():19-23. PubMed ID: 8869464
[TBL] [Abstract][Full Text] [Related]
13. Long-term treatment course of a patient with mild haemophilia A who developed a high titre factor VIII inhibitor.
Iioka F; Shimomura D; Nakamura F; Ohno H; Yada K; Nogami K; Shima M
Haemophilia; 2014 Nov; 20(6):e402-4. PubMed ID: 25354772
[No Abstract] [Full Text] [Related]
14. Hemophilia factor VIII therapy. Immunological tolerance. A clinical perspective.
White GC; Greenwood R; Escobar M; Frelinger JA
Haematologica; 2000 Oct; 85(10 Suppl):113-6. PubMed ID: 11187862
[TBL] [Abstract][Full Text] [Related]
15. Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment.
Earnshaw SR; Graham CN; McDade CL; Spears JB; Kessler CM
Haemophilia; 2015 May; 21(3):310-319. PubMed ID: 25688580
[TBL] [Abstract][Full Text] [Related]
16. [Development of inhibitor against hemophilia and prevention and management strategies forpatients with hemophilia].
Wu RH; Wei QQ
Zhonghua Er Ke Za Zhi; 2013 Aug; 51(8):631-4. PubMed ID: 24225299
[No Abstract] [Full Text] [Related]
17. Antibodies to factor VIII in hemophilia A patients.
Brackmann HH; Schwaab R; Effenberger W; Hess L; Hanfland P; Oldenburg J
Vox Sang; 2000; 78 Suppl 2():187-90. PubMed ID: 10938950
[TBL] [Abstract][Full Text] [Related]
18. Hemophilia. Strategies for the treatment of inhibitor patients.
Ingerslev J
Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
[TBL] [Abstract][Full Text] [Related]
19. Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity.
Oldenburg J; Lacroix-Desmazes S; Lillicrap D
Haematologica; 2015 Feb; 100(2):149-56. PubMed ID: 25638804
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors - cellular aspects and novel approaches for tolerance.
Scott DW
Haemophilia; 2014 May; 20 Suppl 4(0 4):80-6. PubMed ID: 24762281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
